Du är här

2016-01-20

GLOBAL BIOENERGIES: GLOBAL BIOENERGIES launches a private placement

This document may not be distributed, directly or indirectly, in the United
States, Canada, Australia or Japan.

GLOBAL BIOENERGIES launches a private placement

Evry, 20 January 2016
-

Global Bioenergies (Alternext Paris: ALGBE) ("the Company") today announced
that it is launching an increase in its share capital through the issue of
new ordinary shares, without preferential subscription rights, to qualified
investors, pursuant to the eighth resolution
of the Combined General Shareholders Meeting held on 3 June 2015, in the
amount of approximately €6 million, i.e. approximately 10% of the Company's
share capital. Application will be made for the new shares to be admitted for
trading on Euronext Paris.

The funds will be raised in accordance with Article L.411-2 II of the French
Monetary and Financial Code (Code monétaire et financier
) (the "Private Placement"), from domestic and international qualified
investors, notably excluding Canada, Australia and Japan. They will be used
to further the development of the isobutene process and to launch commercial
roll-out.

The CM-CIC Investissement SCR and CM-CIC Innovation funds have undertaken,
under certain conditions, to subscribe to the capital increase for a total of
18% of the funds to be raised, in an amount not to exceed €1.8 million, and
at a maximum price of €25.5 per share. The FCPIs BioSanté 2013, BioSanté
2014, Masseran Innovation VI and Seventure Preference Innovation 2013
high-tech mutual funds have undertaken, under certain conditions, to subscribe
to the capital increase for a total amount of €1.7 million, at a maximum
price of €25.5 per share.

According to the terms of the eighth resolution of the Combined General
Shareholders Meeting held on 3 June 2015, the issue price of the new shares
will be at least equal to the weighted average price of the Company's share
on the Euronext Paris Alternext market in the last three trading sessions
prior to setting the issue price, which may be reduced by a maximum discount
of 20%, within the limit of 17,5% of the Company's share capital, i.e. a
maximum of 504 039 new shares.

Marc Delcourt, CEO at Global Bioenergies says: "The funds raised through this
private placement will enable the Company to switch to full-scale commercial
roll-out. We are expecting to sign several significant industrial agreements
starting in 2016."

The Private Placement is being conducted by Gilbert Dupont (Paris) and Baader
Bank AG (Munich) as joint lead managers and joint bookrunners. The issue does
not require registration with the French financial markets authority (AMF) or
publication of a prospectus.

The final terms and results of the Private Placement will be announced as soon
as possible.

Legal notice

This document may not be distributed, directly or indirectly, in or into the
United States. This document is not an offer of securities for sale nor the
solicitation of an offer to purchase securities in the United States.
Securities may not be offered or sold in the United States absent
registration under the U.S. Securities Act of 1933, as amended, or an
exemption from registration. The shares of the Company have not been and will
not be registered under the U.S. Securities Act, and the Company does not
intend to make a public offer of its securities in the United States.

About GLOBAL BIOENERGIES

Global Bioenergies is one of the few companies worldwide, and the only one in
Europe, that is developing a process to convert renewable resources into
hydrocarbons through fermentation. The Company initially focused its efforts
on the production of isobutene, one of the most important petrochemical
building blocks that can be converted into fuels, plastics, organic glass and
elastomers. Global Bioenergies continues to improve the performances of its
process, operates its industrial pilot, has begun the construction of its
demo plant in Germany, and is preparing the first full-scale plant through a
joint venture with Cristal Union, named IBN-One. The company also replicated
its achievement to propylene and butadiene, two members of the gaseous
olefins family, key molecules at the heart of petrochemical industry. Global
Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE) and
on the Alternext Oseo Innovation index.

Should you like to be kept informed, subscribe to our
news feed on www.global-bioenergies.com

Follow us on Twitter:
@GlobalBioenergi

Contact

GLOBAL BIOENERGIES

François-Henri Sahakian
Chief Financial Officer
Phone: +33 (0)1 64 98 20 50
Email:invest@global-bioenergies.com

----
| |
| |
----

This document may not be distributed, directly or indirectly, in the United
States, Canada, Australia or Japan.

----
| |
| |
----
PRESS RELEASE
http://hugin.info/166909/R/1980269/725406.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GLOBAL BIOENERGIES via Globenewswire

HUG#1980269

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.